Yang Nong, a chief physician and doctoral supervisor, currently serves as the Vice President of the Second Peoples Hospital of Hunan Province, the leader of the oncology department, and the head of the "Yang Nong Famous Doctor Clinic"/"Yang Nong Famous Doctor Expert Team Clinic". He is also a long-term expert at Hainan Cancer Hospital and Hainan Chengmei Hospital, a chief expert of the National Major Scientific and Technological Special Project, a member of the Lung Cancer Special Committee of the National Tumor Quality Control Center, the director of the Hunan Provincial Key Laboratory of Precision Diagnosis and Treatment of Lung Cancer, and the director of the Hunan Provincial Respiratory Tumor Clinical Medicine Research Center. He has been dedicated to precision targeted therapy for lung cancer and gastrointestinal tumors, as well as to challenging recurrent and resistant clinical cases, scientific research, and teaching for nearly 30 years.

He was honored with the title of "Outstanding Model of National Famous Doctors" in the 6th edition, and has been recommended as "Annual Excellent Doctor" by patients across the country for eight consecutive years, as well as being awarded the title of "First Brain Doctor and Famous Doctor". He has authored national guidelines, received the third prize of Hunan Provincial Science and Technology Award, garnered over 500,000 fans across the internet, and achieved over 120 million views of his anti-cancer science popularization videos.

Specialties: Precision treatment of lung cancer, breakthroughs in complex, recurrent, drug-resistant, and brain-metastatic conditions; individualized and precise treatment for brain metastases of lung cancer; early diagnosis of pulmonary nodules and lung cancer; personalized and comprehensive diagnosis and treatment for various solid tumors; clinical trials of the latest immunotherapy/targeted therapy drugs.

With nearly 30 years of experience in precision immunotherapy for lung cancer, I have led nearly 400 phase I-III clinical trials of new anticancer drugs (including national Class 1 new drugs), and am particularly skilled in handling complex cases such as refractory, recurrent, and drug-resistant conditions, as well as brain metastases.

·Early diagnosis and treatment of pulmonary nodules and lung cancer.

·He is also proficient in the comprehensive diagnosis and treatment of multiple cancer types, individualized treatment, and interdisciplinary collaboration across various solid tumors (such as stomach, intestine, brain, etc.).

·Managing the "Lung Cancer Immunotherapy Patient Group", conducting long-term follow-up management for lung cancer patients who have achieved long-term survival, and accumulating rich clinical experience.

Precision immune-targeted therapy for lung cancer/gastrointestinal tumors, difficult recurrent drug resistance; individualized precision therapy for lung cancer brain metastases; early diagnosis of lung nodules and lung cancer; clinical trials of the latest immune/targeted therapeutic agents.

Member of Lung Cancer Quality Control Committee of the National Cancer Quality Control Center 
Vice Chairman China Medical Education Association 
Vice Chairman, Oncology Clinical Research Innovation and development Committee, China Medical Education Association 
Director of the Chinese Society of Clinical Oncology and Member of the Specialized Committee on Tumor Immunotherapy, Non-Small Cell Lung Cancer, and Drug Development 
Standing member of Anti-tumor Drugs Committee and Lung Cancer Committee of China Anti-Cancer Association 
Member of Oncology Branch of Chinese Physicians Association 
Chairman of Precision Medicine Specialized Committee of Hunan Anti-cancer Association 
Chairman of Clinical Oncology Branch, Hunan Geriatrics Society

In the past five years, he has published 45 SCI papers as the first or corresponding author in Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology and other international journals, with a cumulative impact factor of 330. Has obtained 4 scientific research achievements above the provincial level, which have been orally reported or exhibited in poster sessions at international conferences such as AACR, ASCO, WCLC and GAP, etc. Has published 46 conference papers, of which 3 are oral presentations, and has been mainly involved in the research and development of 5 original 1.1 new drugs, and has been approved for 3 patents. 
Has participated in the compilation of the Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Primary Lung Cancer, the Chinese Society of Clinical Oncology Expert Consensus on Perioperative Treatment of Early-stage Lung Cancer, the Chinese Medical Association Clinical Guidelines for Lung Cancer, the Ministry of Health Guidelines for the Standardized Diagnosis and Treatment of Common Tumors in Municipal and County Hospitals, the Chinese Expert Consensus for Multidisciplinary Team Diagnosis and Treatment of Lung Cancer, and has also taken part in the formulation of the guiding principles of the CDEs clinical trials of many anticancer drugs. As a principal investigator, he has designed, organized and participated in nearly 300 Phase I-III clinical trials, with more than 30 clinical studies in progress, and has led clinical studies on a number of innovative anti-cancer drugs as Leading PI.